Arlene Weintraub

Arlene Weintraub

Award-winning science journalist

Arlene Weintraub is a science journalist and author with 20 years of experience writing about healthcare, pharmaceuticals and biotechnology.

  • 116
    stories
  • 100K
    words
116
stories for
13
publications
Arlene Weintraub's stories for
Show all
Stringio article
Xconomy

Retrophin, Headed by Controversial Hedge Fund Chief, Raises $4M ...

New York-based biotech company Retrophin announced this morning that it has completed a $4 million Series A round led by MSMB Capital, a life sciences hedg

Open uri20130118 16088 13nrkns article
Xconomy

Amazon and Pfizer Fuel Ever-Growing Frenzy in the Market for Pet ...

As much as I hate clichés, I can't resist using them to describe what's been going on lately in the pet-products business. So here goes: It's raining cats

Xconomy

Agios and Celgene: Anatomy of an Ultra-Valuable Biotech Marriage ...

It wouldn't be much of an over-statement to say Cambridge, MA-based Agios' $150 million cancer-drug development deal with biotech giant Celgene is unpreced

Stringio article
Xconomy

Coronado Biosciences Debuts on Nasdaq, Moves Two Lead Drugs ...

The path to becoming a publicly listed company chosen by Coronado Biosciences (NASDAQ: ]) was anything but conventional, but it seems to be working for the

Xconomy

Enlight Bio's Knode Advances Social Network for Pharma | Xconomy

Enlight Biosciences, a pharma industry-backed entrepreneurial venture, unveiled its newest portfolio company today, Knode. The Cambridge, MA-based startup,

Xconomy

Everyday Health is Out to Dominate Media via Video, Apps, and ...

When dot-com entrepreneurs Benjamin Wolin and Michael Keriakos founded Everyday Health in 2002, everyone thought they were nuts. Their idea was to take wel

Open uri20130118 16088 1xivt82 article
Xconomy

Gamification Hits Healthcare as Startups Vie for Cash and Partners ...

Would working out at the gym be easier if you earned cash every time you hopped on the treadmill? Boston-based startup GymPact is betting that millions of

Open uri20130118 13672 1yp5qvf article
Xconomy

Genentech Pours $95M Into Constellation's Drug Platform | Xconomy

Cambridge, MA-based Constellation Pharmaceuticals is announcing today that it has formed a major partnership with Roche's Genentech unit, based in South Sa

Open uri20130118 13672 86jkjl article
Xconomy

Giffen Solutions, Created by Fed-Up Doc, Connects MDs and ...

Michael Nusbaum rarely thought twice about giving his personal cell phone number to patients after he operated on them. Nusbaum is a bariatric surgeon at N

Stringio article
Xconomy

Merck Fine-Tunes Biosimilars Strategy as FDA Guidelines Loom ...

The pharmaceutical world is abuzz over rumors that the FDA is on the verge of releasing its guidelines for how companies should develop generic versions of

Open uri20130118 13672 1bouhq4 article
Xconomy

Merck Oncology Chief Heads to ASCO With High Hopes for New ...

At the annual conference of the American Society of Clinical Oncology (ASCO), starting tomorrow in Chicago, drug giant Merck will be presenting no less tha

Stringio article
Xconomy

Option to Buy: The New Face of Biotech Funding? | Xconomy

When Cambridge, MA-based Warp Drive Bio launched on January 10, the startup was as notable for its financing structure as it was for its technology---maybe

Open uri20130118 13672 eevq1u article
Xconomy

Pet Dogs Help Biotech Startups Find New Weapons to Fight Cancer ...

A few weeks back, a black-and-white terrier mix named Chance entered a clinical trial for a drug that may offer a completely new way to combat cancer---not

Open uri20130118 9224 1it8bqo article
Xconomy

PetFlow Paws its Way to the Top of Facebook, Sniffs Out Growth ...

In February 2011, the website Business Insider quoted PetFlow.com co-founder Alex Zhardanovsky criticizing the pioneer of the online pet-supply business---

Xconomy

Transparency Launches as Linux of Drug Development | Xconomy

When Tomasz Sablinski was working in pharmaceutical R&D, he was often frustrated by the demand for secrecy in the clinical trials process---a misdirect